Tirzepatide
- Generic Name
- Tirzepatide
- Brand Names
- Mounjaro
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2023788-19-2
- Unique Ingredient Identifier
- OYN3CCI6QE
- Background
Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Dual GIP/GLP-1 agonists gained increasing attention as new therapeutic agents for glycemic and weight control as they demonstrated better glucose control and weight loss compared to selective GLP-1 receptor agonists in preclini...
- Indication
Tirzepatide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. In Europe, it may be used as monotherapy or in combination with other drugs used to treat diabetes.
...
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
A Study to Measure Stomach Emptying in Overweight Non-diabetic and Diabetic Participants Using Tirzepatide
- Conditions
- Interventions
- First Posted Date
- 2020-05-29
- Last Posted Date
- 2024-01-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 36
- Registration Number
- NCT04407234
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, Hialeah, Florida, United States
A Study of Tirzepatide in Overweight and Very Overweight Participants
- Conditions
- Interventions
- First Posted Date
- 2020-03-17
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 114
- Registration Number
- NCT04311411
- Locations
- 🇺🇸
Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States
🇺🇸Indiana University School of Medicine, Indianapolis, Indiana, United States
🇺🇸Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 13299
- Registration Number
- NCT04255433
- Locations
- 🇦🇺
GenesisCare, Murdoch, Western Australia, Australia
🇺🇸Valley Research, Fresno, California, United States
🇺🇸AMCR Institute, Escondido, California, United States
A Study of Tirzepatide in Chinese Participants With Type 2 Diabetes Mellitus
- First Posted Date
- 2020-01-22
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 24
- Registration Number
- NCT04235959
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, China
🇨🇳West China Hospital Sichuan University, Cheng Du, Sichuan, China
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight
- First Posted Date
- 2019-12-03
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 2539
- Registration Number
- NCT04184622
- Locations
- 🇺🇸
National Research Institute - Wilshire, Los Angeles, California, United States
🇺🇸University Clinical Investigators, Inc., Tustin, California, United States
🇺🇸Clinvest Research LLC, Springfield, Missouri, United States
A Study of the Effect of Tirzepatide on How the Body Handles Birth Control Pills in Healthy Female Participants
- First Posted Date
- 2019-11-21
- Last Posted Date
- 2023-03-27
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 40
- Registration Number
- NCT04172987
- Locations
- 🇺🇸
Covance Dallas, Dallas, Texas, United States
A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)
- First Posted Date
- 2019-11-18
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 196
- Registration Number
- NCT04166773
- Locations
- 🇺🇸
Texas Diabetes & Endocrinology, P.A., Round Rock, Texas, United States
🇯🇵Kumamoto Shinto General Hospital, Kumamoto, Japan
🇺🇸Diabetes & Endocrinology Consultants, PC, Morehead City, North Carolina, United States
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo)
- First Posted Date
- 2019-09-18
- Last Posted Date
- 2023-01-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 917
- Registration Number
- NCT04093752
- Locations
- 🇨🇳
Huizhou Municipal Central Hospital, Huizhou, Guangdong, China
🇨🇳Hebei Medical University, Hengshui Shi, Hebei, China
🇦🇺Illawarra Shoalhaven Local Health District, Wollongong, New South Wales, Australia
A Study to Measure Energy Expenditure and Food Intake in Participants With Obesity Using Tirzepatide
- First Posted Date
- 2019-09-09
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 55
- Registration Number
- NCT04081337
- Locations
- 🇺🇸
Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States
A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2019-08-08
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 42
- Registration Number
- NCT04050553
- Locations
- 🇦🇹
Universitätsklinikum Graz, Graz, Steiermark, Austria
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.